ReviewAlcoholism, clinical and experimental research2016
Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development.
Review in Alcoholism, clinical and experimental research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Pooled it
- The Etiologic, Theory-Based, Ontogenetic Hierarchical Framework of Alcohol Use Disorder: A Translational Systematic Review of Reviews.Psychological bulletin · 2021Pooled it
- Naltrexone effects on subjective responses to alcohol in the human laboratory: A systematic review and meta-analysis.Addiction biology · 2019Pooled it
- Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review.Alcoholism, clinical and experimental research · 2019Pooled it
- Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial.The American journal of psychiatry · 2026Trial
- Evaluation of glycine treatment for reducing alcohol craving and self-administration in individuals with alcohol use disorder: A human laboratory trial.Alcohol, clinical & experimental research · 2025Trial
- A practice quit model to test early efficacy of medications for alcohol use disorder in a randomized clinical trial.Psychopharmacology · 2024Trial
- Baseline C-reactive protein levels are predictive of treatment response to a neuroimmune modulator in individuals with an alcohol use disorder: a preliminary study.The American journal of drug and alcohol abuse · 2023Trial
- Effects of ibudilast on central and peripheral markers of inflammation in alcohol use disorder: A randomized clinical trial.Addiction biology · 2022Trial
- Ibudilast attenuates alcohol cue-elicited frontostriatal functional connectivity in alcohol use disorder.Alcoholism, clinical and experimental research · 2021Trial
- Alcohol use disorder severity moderates clinical response to varenicline.Alcoholism, clinical and experimental research · 2021Trial
- Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial.Translational psychiatry · 2021Trial
- Trial
- Advancing Precision Medicine for Alcohol Use Disorder: Replication and Extension of Reward Drinking as a Predictor of Naltrexone Response.Alcoholism, clinical and experimental research · 2019Trial
- The Interplay Between Subjective Response to Alcohol, Craving, and Alcohol Self-Administration in the Human Laboratory.Alcoholism, clinical and experimental research · 2019Trial
- Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.JAMA psychiatry · 2019Trial
- Cannabidiol and Alcohol Use Disorders: An Updated Review of Therapeutic Potential.Alcohol, clinical & experimental research · 2026Review
- Article
- Empirical Derivation and Prediction of Treatment Trajectories in Harmonized AUD Clinical Trial Datasets.Addiction biology · 2025Article
- Glucagon-like Peptide-1 Receptor Agonists: A New Frontier in Treating Alcohol Use Disorder.Brain sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
For more than 25 years, advances have been made in developing medications to treat alcohol use disorder (AUD), highlighted by the U.S. Food and Drug Administration's approval of naltrexone (oral and long-acting) and acamprosate. Despite this progress, more work remains to be done in this area because these medications, although effective for some people, do not work for everyone. A high priority for the National Institute on Alcohol Abuse and Alcohol is to put into place a solid infrastructure to aid in the development of medications that are more effective than those currently available and with few side effects. Medication development, especially for a disorder as complex as AUD, is challenging and involves multiple phases, including discovery of "druggable" targets, preclinical studies, human clinical trials, and the adoption and implementation of the new medication into mainstream medicine. A successful medications development program requires clearly established goals for each phase to ensure that a candidate compound is not trapped in one particular phase, a condition known as "the valley of death." In this article, the phases of medication development are described as they apply to AUD, and specific goals of each phase are identified for the next decade. In addition, several important crosscutting themes are outlined for each phase, all of which are essential for advancing medications development. These include identifying and validating screening models and druggable targets, making use of precision medicine, and establishing partnerships among key stakeholders. Our goal in writing this article is to provide a guide on medications development that will aid the alcohol research community in planning, testing, and developing medications for AUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.